Literature DB >> 20631138

Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model.

Aeron C Hurt1, Siti Sarah Nor'e, James M McCaw, Helen R Fryer, Jennifer Mosse, Angela R McLean, Ian G Barr.   

Abstract

To determine the relative fitness of oseltamivir-resistant strains compared to susceptible wild-type viruses, we combined mathematical modeling and statistical techniques with a novel in vivo "competitive-mixtures" experimental model. Ferrets were coinfected with either pure populations (100% susceptible wild-type or 100% oseltamivir-resistant mutant virus) or mixed populations of wild-type and oseltamivir-resistant influenza viruses (80%:20%, 50%:50%, and 20%:80%) at equivalent infectivity titers, and the changes in the relative proportions of those two viruses were monitored over the course of the infection during within-host and over host-to-host transmission events in a ferret contact model. Coinfection of ferrets with mixtures of an oseltamivir-resistant R292K mutant A(H3N2) virus and a R292 oseltamivir-susceptible wild-type virus demonstrated that the R292K mutant virus was rapidly outgrown by the R292 wild-type virus in artificially infected donor ferrets and did not transmit to any of the recipient ferrets. The competitive-mixtures model was also used to investigate the fitness of the seasonal A(H1N1) oseltamivir-resistant H274Y mutant and showed that within infected ferrets the H274Y mutant virus was marginally outgrown by the wild-type strain but demonstrated equivalent transmissibility between ferrets. This novel in vivo experimental method and accompanying mathematical analysis provide greater insight into the relative fitness, both within the host and between hosts, of two different influenza virus strains compared to more traditional methods that infect ferrets with only pure populations of viruses. Our statistical inferences are essential for the development of the next generation of mathematical models of the emergence and spread of oseltamivir-resistant influenza in human populations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631138      PMCID: PMC2937593          DOI: 10.1128/JVI.00373-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Modelling strategic use of the national antiviral stockpile during the CONTAIN and SUSTAIN phases of an Australian pandemic influenza response.

Authors:  Jodie McVernon; James M McCaw; Terence M Nolan
Journal:  Aust N Z J Public Health       Date:  2010-04       Impact factor: 2.939

Review 2.  Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.

Authors:  Aeron C Hurt; Hui-Ting Ho; Ian Barr
Journal:  Expert Rev Anti Infect Ther       Date:  2006-10       Impact factor: 5.091

3.  Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.

Authors:  Michael Z Wang; Chun Y Tai; Dirk B Mendel
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

4.  Oral oseltamivir treatment of influenza in children.

Authors:  R J Whitley; F G Hayden; K S Reisinger; N Young; R Dutkowski; D Ipe; R G Mills; P Ward
Journal:  Pediatr Infect Dis J       Date:  2001-02       Impact factor: 2.129

5.  Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors.

Authors:  Mikhail Matrosovich; Tatyana Matrosovich; Jackie Carr; Noel A Roberts; Hans-Dieter Klenk
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.

Authors:  C Y Tai; P A Escarpe; R W Sidwell; M A Williams; W Lew; H Wu; C U Kim; D B Mendel
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

7.  Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.

Authors:  L V Gubareva; M N Matrosovich; M K Brenner; R C Bethell; R G Webster
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

Review 8.  Lessons for human influenza from pathogenicity studies with ferrets.

Authors:  H Smith; C Sweet
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

9.  Genomic diversity of oseltamivir-resistant influenza virus A (H1N1), Luxembourg, 2007-08.

Authors:  Nancy A Gerloff; Jacques R Kremer; Jöel Mossong; Matthias Opp; Claude P Muller
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

10.  Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy.

Authors:  Joseph T Wu; Gabriel M Leung; Marc Lipsitch; Ben S Cooper; Steven Riley
Journal:  PLoS Med       Date:  2009-05-19       Impact factor: 11.069

View more
  41 in total

1.  The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses.

Authors:  Wai Lan Wu; Siu-Ying Lau; Yixin Chen; Genyan Wang; Bobo Wing-Yee Mok; Xi Wen; Pui Wang; Wenjun Song; Tianwei Lin; Kwok-Hung Chan; Kwok-Yung Yuen; Honglin Chen
Journal:  Antiviral Res       Date:  2011-11-25       Impact factor: 5.970

2.  Analysis of host genetic diversity and viral entry as sources of between-host variation in viral load.

Authors:  Andrew R Wargo; Alison M Kell; Robert J Scott; Gary H Thorgaard; Gael Kurath
Journal:  Virus Res       Date:  2012-01-30       Impact factor: 3.303

3.  Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.

Authors:  Kanyarat Ruangrung; Ornpreya Suptawiwat; Kittipong Maneechotesuwan; Chompunuch Boonarkart; Warunya Chakritbudsabong; Jirawatna Assawabhumi; Parvapan Bhattarakosol; Mongkol Uiprasertkul; Pilaipan Puthavathana; Witthawat Wiriyarat; Anan Jongkaewwattana; Prasert Auewarakul
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

4.  The R292K mutation that confers resistance to neuraminidase inhibitors leads to competitive fitness loss of A/Shanghai/1/2013 (H7N9) influenza virus in ferrets.

Authors:  Hui-Ling Yen; Jie Zhou; Ka-Tim Choy; Sin Fun Sia; Ooiean Teng; Iris H Ng; Vicky J Fang; Yunwen Hu; Wei Wang; Benjamin J Cowling; John M Nicholls; Yi Guan; Joseph Sriyal Malik Peiris
Journal:  J Infect Dis       Date:  2014-06-20       Impact factor: 5.226

5.  Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques.

Authors:  Mitsutaka Kitano; Yasushi Itoh; Makoto Kodama; Hirohito Ishigaki; Misako Nakayama; Hideaki Ishida; Kaoru Baba; Takahiro Noda; Kenji Sato; Yoichiro Nihashi; Takushi Kanazu; Ryu Yoshida; Ryuzo Torii; Akihiko Sato; Kazumasa Ogasawara
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

6.  The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets.

Authors:  Lady Tatiana Pinilla; Benjamin P Holder; Yacine Abed; Guy Boivin; Catherine A A Beauchemin
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

7.  Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.

Authors:  Diana D Y Wong; Ka-Tim Choy; Renee W Y Chan; Sin Fun Sia; Hsin-Ping Chiu; Peter P H Cheung; Michael C W Chan; J S Malik Peiris; Hui-Ling Yen
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

Review 8.  Complexities in Ferret Influenza Virus Pathogenesis and Transmission Models.

Authors:  Jessica A Belser; Alissa M Eckert; Terrence M Tumpey; Taronna R Maines
Journal:  Microbiol Mol Biol Rev       Date:  2016-07-13       Impact factor: 11.056

9.  Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks.

Authors:  Jenna E Achenbach; Richard A Bowen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  The role of virulence in in vivo superinfection fitness of the vertebrate RNA virus infectious hematopoietic necrosis virus.

Authors:  Alison M Kell; Andrew R Wargo; Gael Kurath
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.